TY - JOUR TI - Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant AU - Zhang, Cheng AU - Wang, Xiao-Qi AU - Zhang, Rong-Li AU - Liu, Fang AU - Wang, Yi AU - Yan, Zhi-Ling AU - Song, Yong-Ping AU - Yang, Ting AU - Li, Ping AU - Wang, Zhen AU - Ma, Ying-Ying AU - Gao, Lei AU - Liu, Yao AU - Gao, Li AU - Kong, Pei-Yan AU - Liu, Jun AU - Tan, Xu AU - Zhong, Jiang F. AU - Chen, Yu-Qing AU - Liang, Ai-Bin AU - Ren, Jin-Hua AU - Li, Zhen-Yu AU - Cao, Jiang AU - Gao, Quan-Li AU - Zhou, Jian AU - Gao, Ying AU - Zhang, Ding AU - Fan, Fang-Yi AU - Han, Ming-Zhe AU - Gale, Robert Peter AU - Zhang, Xi T2 - Leukemia AB - Safety and efficacy of allogeneic anti-CD19 chimeric antigen receptor T cells (CAR-T cells) in persons with CD19-positive B-cell acute lymphoblastic leukemia (B-ALL) relapsing after an allotransplant remain unclear. Forty-three subjects with B-ALL relapsing post allotransplant received CAR-T cells were analyzed. 34 (79%; 95% confidence interval [CI]: 66, 92%) achieved complete histological remission (CR). Cytokine release syndrome (CRS) occurred in 38 (88%; 78, 98%) and was ≥grade-3 in 7. Two subjects died from multiorgan failure and CRS. Nine subjects (21%; 8, 34%) developed ≤grade-2 immune effector cell-associated neurotoxicity syndrome (ICANS). Two subjects developed ≤grade-2 acute graft-versus-host disease (GvHD). 1-year event-free survival (EFS) and survival was 43% (25, 62%). In 32 subjects with a complete histological remission without a second transplant, 1-year cumulative incidence of relapse was 41% (25, 62%) and 1-year EFS and survival, 59% (37, 81%). Therapy of B-ALL subjects relapsing post transplant with donor-derived CAR-T cells is safe and effective but associated with a high rate of CRS. Outcomes seem comparable to those achieved with alternative therapies but data from a randomized trial are lacking. DA - 2020/10/19/ PY - 2020 DO - 10.1038/s41375-020-01056-6 DP - www.nature.com SP - 1 EP - 8 LA - en SN - 1476-5551 UR - https://www.nature.com/articles/s41375-020-01056-6 Y2 - 2020/10/19/21:52:05 ER -